Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml

AIDS

Volumn 20, Issue 5, 2006, Pages 778-779

  Waters, Laura ^a   Mandalia, S ^a   Asboe, David ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE AMPLIFICATION; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIREMIA; VIRUS LOAD;

CHI-SQUARE DISTRIBUTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL LOAD;

EID: 33745081536     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000216381.37679.69     Document Type: Article

References (3)

1. Raboud JM, Rae S, Hogg RS, Yip B, Sherlock CH, Harrigan PR, et al. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virological response than suppression below the limit of quantitation. J Infect Dis 1999; 180:1347-1350.
2. De Mendoza C, Soriano V, Perez-Olmeda M, Rodes B, Casas E, Gonzalez-Lahoz J. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. J Hum Virol 1999; 2:344-349.
3. Pilcher CD, Miller WC, Beatty ZA, Eron JJ. Detectable HIV-1 RNA at levels below quantifiable limits by ampiclor HIV-1 monitor is associated with virological relapse in antiretroviral therapy. AIDS 1999; 13:1337-1342.